



PRESS RELEASE

Transfer of 29,348,550 THERAMetrics shares to THERAMetrics holding AG as a follow up to the contractual commitments previously assumed as part of the business combination executed in September 2013 between the Research Division of the Pierrel Group and THERAMetrics.

Capua, 3 August 2015 – Pierrel S.p.A. (the “**Company**”) announces that today the transfer of 29,348,550 shares in THERAMetrics to THERAMetrics holding AG (“**THERAMetrics**”, previously mondoBIOTECH holding AG).

The transfer was executed pursuant to the agreements signed as part of the Business combination between the aforementioned Research Division of the Pierrel Group and THERAMetrics. In addition particularly, as part of the negotiations between Pierrel and Fin Posillipo S.p.A. (then the holder of some 74% and some 26% of the share capital of Pierrel Research International AG (“**PRINT**”)), on the one hand, and THERAMetrics, on the other, the parties established that the allocation of the share capital of PRINT in the share capital of THERAMetrics had to be done on the basis of exchange of 2.75 THERAMetrics shares for every PRINT share allocated to the company and to Fin Posillipo S.p.A.

Such an exchange ratio was determined by the parties on a fully diluted basis, i.e. by assuming complete exercise of the 14 million warrants issued by THERAMetrics, that granted to the related holder the right, exercisable before 17 July 2015, to subscribe for 1 THERAMetrics share for every warrant and, as a result, up to a maximum of 14 million THERAMetrics shares, at a determined strike price.

As part of the agreements an adjustment mechanism was however provided for the THERAMetrics shares assigned as a result of the transaction; this mechanism determined that, in the event that such warrants were not exercised, in part or full, Pierrel and Fin Posillipo S.p.A. would have transferred to THERAMetrics, each of them in proportion to the share held in the share capital of PRINT at the date of the allocation of the relative shares in THERAMetrics, 2.75 THERAMetrics shares for each warrant not exercised before the stated time.

Subsequent to the expiry of the timeframe of 17 July 2015, without the warrants being exercised by the holder of the right, THERAMetrics thus requested the Company and Fin Posillipo S.p.A. to transfer 29,348,550 and 9,151,450 THERAMetrics shares respectively, according to the terms described above.

As a result of the transaction described, executed today, the shareholding held by the Company and Fin Posillipo S.p.A. in the share capital of THERAMetrics are adjusted to some 27% and some 31% respectively, in the related share capital. The effects of the transaction are the subject of a thorough investigation as of the date of the present press release.

* * *

Pierrel S.p.A. is a global supplier to the pharmaceutical, biopharmaceutical and life science industries, specialising in the discovery of medicinal product candidates and the repositioning of existing drugs for new therapeutic indications and clinical research (TCRDO Division), pharmaceutical production (Contract Manufacturing Division) and the development, registration and licensing of new drugs and medical devices (Pharma Division).

Pierrel Group is listed on the MTA exchange which is organised and managed by Borsa Italiana and boasts over 60 years’ experience in the pharmaceutical sector, being one of Europe’s leading producers of local and dental anaesthetics. The TCRDO Division, working across Europe and the US, is recognised internationally for its research and development into tech based clinical research innovations with its Drug Repositioning and Repurposing System (“**DRR2.0**”) and Integrated Clinical Development Services (“**ICDS**”) for the pharmaceutical, biotechnology and biomedical industries. The parent company of the TCRDO Division (**THERAMetrics holding AG**, listed in the Swiss stock exchange) holds the innovative interactive **DRR2.0** platform, which runs on a database of 24 million scientific publications (being virtually all of those



available in the field of biomedical literature), of over 4,900 drugs and of 9,400 illnesses. With this data, never before collected in one place and stored in the cloud, the Search and Match algorithm can show a researcher not only the candidate drug but also a detailed road map with indications of possible second medical uses. The database can be searched by molecule or by illness. Pierrel also has a production unit in Capua, close to Naples, Italy, that has been authorised by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the aseptic production of injectable medicines. The subsidiary Pierrel Pharma S.r.l. has registered and distributes the Orabloc® dental anaesthetic in Canada, US, Russia and Europe.

The registered office of Pierrel S.p.A. is in Capua (CE), Italy.

For further information:

Pierrel S.p.A.

Investor Relations

Dr Raffaele Petrone

e-mail:

investor.relations@pierrelgroup.com

tel. +39 0823 626 111

fax +39 0823 626 228

Global Consult S.r.l.

Media Relations

Rossana Del Forno

e-mail:

areacomunicazione@globalconsultsrl.com

tel. +39 333 6178665